Articles related to HODGKIN LYMPHOMA (HL)
Long-Term Childhood Hodgkin Lymphoma (HL) Survivors Have Increased Risk of Neurocognitive Impairment
According to the researchers, “The findings from this study suggest that survivors of [HL] require life-long regular screening for early detection of chronic health conditions and that healthy lifestyle behaviors need to be strongly encouraged as these survivors appear more vulnerable to neurocognitive and psychosocial sequelae from these events.”
Neurology March 29th 2022
Hodgkin Lymphoma: PET-Adaptive Approach in Bulky Hodgkin Lymphoma
The authors of this JCO study used a PET-adaptive approach to reduce the need for radiotherapy (RT) in early PET (-) disease and escalate therapy in patients with PET (+) disease. The study reports excellent outcomes for the approach, which allowed omission of radiotherapy in more than three-quarters of patients.
Hematology January 19th 2022
Phase II Trial of Pembrolizumab + Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as SLT for Rel/Ref Classical Hodgkin Lymphoma (cHL)
Second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT).
Hematology December 21st 2021